ANI Pharmaceuticals (NASDAQ:ANIP) Issues FY 2025 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) updated its FY 2025 earnings guidance on Tuesday. The company provided EPS guidance of 6.120-6.490 for the period, compared to the consensus EPS estimate of 5.560. The company issued revenue guidance of $756.0 million-$776.0 million, compared to the consensus revenue estimate of $724.9 million.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on ANIP. StockNews.com lowered ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday. Leerink Partners began coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday. Finally, Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $77.71.

ANI Pharmaceuticals Price Performance

NASDAQ:ANIP opened at $58.46 on Tuesday. ANI Pharmaceuticals has a 52 week low of $52.50 and a 52 week high of $70.81. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The stock has a market capitalization of $1.23 billion, a PE ratio of -106.29 and a beta of 0.74. The stock’s 50-day moving average price is $57.23 and its 200-day moving average price is $58.13.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 7,500 shares of the business’s stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the transaction, the chief financial officer now owns 154,468 shares in the company, valued at $8,617,769.72. The trade was a 4.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction on Friday, February 21st. The stock was sold at an average price of $60.20, for a total transaction of $60,200.00. Following the sale, the senior vice president now directly owns 68,624 shares of the company’s stock, valued at approximately $4,131,164.80. This trade represents a 1.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,300 shares of company stock valued at $584,009 in the last ninety days. 12.70% of the stock is currently owned by corporate insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.